Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Theralase Technologies Inc TLTFF


Primary Symbol: V.TLT

Healthcare Medical Devices
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops,... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:TLT)

Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy

Newsfile 5 days ago

Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

Newsfile February 20, 2026

Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

Newsfile February 17, 2026

Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

Newsfile February 10, 2026

Theralase(R) Provides Update on Bladder Cancer Clinical Study

Newsfile February 4, 2026

Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

Newsfile February 2, 2026

Canadian Investment Regulatory Organization Trade Resumption - TLT

Canada NewsWire January 12, 2026

Theralase and Ferring ink deal for new bladder cancer study

Trevor Abes  January 12, 2026

Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

Newsfile January 12, 2026
View More News ››

Opinion & Analysis (TSXV:TLT)

Pharmaceutical company treats bladder cancer with new tech

Ryan Dhillon January 8, 2024

Theralase is raising up to $5.3M to complete bladder cancer study

Coreena Robertson November 6, 2023

For Better or Worse? On the Verge of a New Era in Investing

Stockhouse Editorial April 1, 2021

Buzz on the Bullboards: A Big Picture Look at Small-Cap Opportunities

Stockhouse Editorial February 18, 2021

Buzz on the Bullboards: Tracking the Big Movers of 2020

Stockhouse Editorial December 17, 2020

Buzz on the Bullboards: T’is the Season for a Rebound?

Stockhouse Editorial December 3, 2020
View More Opinion ››

Bullboard Posts (TSXV:TLT)

RE:RE:RE:RE:New Press Release - Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy

When the time comes I don't think the sp being at 27c or 2.70 will make a difference.  If they want it and it makes sense the...
Longholder99 - 7 hours ago

RE:RE:RE:RE:New Press Release - Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy

Regarding position building, if you check the total volume every day which means including the ATS it's not nearly as low as it seems...
plantrader - 8 hours ago

RE:RE:RE:New Press Release - Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy

I wouldn't be surprised if there is some position building happening right now. Volumes aren't huge because it would probably...
StevenBirch - 8 hours ago

RE:RE:RE:Stay Tuned...

Been here for 4 or 5 years and have a pile of shares, but lately my patience is wearing thin.They put out news of partnership and share...
gonefishing2022 - 9 hours ago

RE:RE:Stay Tuned...

AA in 2026, new trials in 2026, Ferring and Theralase amazing off the chart results in 2026,possible uplisting in 2026, new financing in...
Legit62 - 12 hours ago

RE:RE:New Press Release - Light-Activated Ruvidar and Interferon Demonstrate Enhanced Efficacy

This is where the 'in 2 years' and the 'long runway' folks miss a nuance in the Micro Cap arena.  If some big dog...
Longholder99 - 14 hours ago
View more Bullboard ››

JZR Gold Inc.

JZR Gold Inc.

JZR Gold Inc., a junior mining resource company, engages in the acquisition, exploration, and development of mineral ...
View More »

Podcasts